Rafael Holdings, Inc. (NYSE:RFL) Stock Short Interest Falls 55.9%

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totaling 348,361 shares, a decline of 55.9% from the September 30th total of 789,108 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average trading volume of 127,973 shares, the days-to-cover ratio is currently 2.7 days.

Rafael Stock Down 2.2%

Shares of RFL traded down $0.03 during mid-day trading on Friday, hitting $1.09. 67,242 shares of the company traded hands, compared to its average volume of 72,806. The company has a market capitalization of $56.94 million, a PE ratio of -1.89 and a beta of 0.35. The business has a 50 day moving average of $1.84 and a 200 day moving average of $1.69. Rafael has a 1-year low of $1.08 and a 1-year high of $3.96.

Rafael (NYSE:RFL) last released its earnings results on Thursday, October 29th. The company reported ($0.18) EPS for the quarter. The company had revenue of $0.24 million during the quarter. Rafael had a negative return on equity of 39.52% and a negative net margin of 3,390.73%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on RFL shares. Wall Street Zen raised shares of Rafael to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rafael in a report on Tuesday, August 25th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Rafael currently has an average rating of “Sell”.

Institutional Investors Weigh In On Rafael

An institutional investor recently bought a new position in Rafael stock. Kahn Brothers Group Inc. purchased a new position in shares of Rafael Holdings, Inc. (NYSE:RFL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 150,493 shares of the company’s stock, valued at approximately $494,000. Kahn Brothers Group Inc. owned 0.29% of Rafael as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.30% of the company’s stock.

About Rafael

Rafael Holdings, Inc (NYSE:RFL) is a diversified holding company with interests in biotechnology and commercial real estate. Through its life sciences operations, the company has focused on developing potential treatments for cancer and other serious diseases, including therapies designed to target the metabolism of cancer cells.

Rafael’s biotechnology activities have been conducted primarily through Rafael Pharmaceuticals, which has researched investigational drug candidates such as devimistat (also known as CPI-613).